Loading
KCNB2 (Potassium voltage-gated channel subfamily B member 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and smooth muscle cells. Channels open or close in response to the voltage difference across the membrane, letting potassium ions pass in accordance with their electrochemical gradient. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarisation.
Open Targets scores its association with cancer at 0.58 (direct and indirect evidence; datatypes literature 0.04, genetic association 0.55, clinical 0.76).
In plain words · KCNB2 (Potassium voltage-gated channel subfamily B member 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCNB2 (Potassium voltage-gated channel subfamily B member 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and smooth muscle cells.
No product in this corpus aims at KCNB2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNB2: RNA tissue enhanced (brain 2 nTPM, lymphoid tissue 2 nTPM, retina 4 nTPM); no normal tissue stained high. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCNB2 tissue; Open Targets ENSG00000182674 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Schmalz et al, Am. J. Physiol, 1998, "Molecular identification of a component of delayed rectifier current in gastrointestinal smooth muscles". Source.
Sources: HGNC HGNC:6232 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92953 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000182674 (association with cancer (MONDO_0004992) 0.58; (GraphQL API, CC0))
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and smooth muscle cells. Channels open or close in response to the voltage difference across the membrane, letting potassium ions pass in accordance with their electrochemical gradient. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarisation. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB1; channel properties depend on the type of alpha subunits that are part of the channel. Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNS1 and KCNS2, creating a functionally diverse range of channel complexes. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Location: Cell membrane; Perikaryon; Cell projection, dendrite (UniProt). Locus 8q21.11 (HGNC).
RNA: tissue enhanced (brain 2 nTPM, lymphoid tissue 2 nTPM, retina 4 nTPM), detected in some normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA KCNB2 tissue · HPA KCNB2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCNB2" OR ABSTRACT:"KCNB2" OR TITLE:"potassium voltage-gated channel subfamily B member 2" OR ABSTRACT:"potassium voltage-gated channel subfamily B member 2" OR TITLE:"Potassium voltage-gated channel subfamily B member 2" OR ABSTRACT:"Potassium voltage-gated channel subfamily B member 2" OR TITLE:"Kv2.2" OR ABSTRACT:"Kv2.2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNB2, not a curated reading list.